Not applicableStudy completedNCT03012789What this trial is testingSurgical Intervention and the NETestWho this might be right forNeuroendocrine TumorGastroenteropancreatic Wren Laboratories LLC 30
Not applicableStudy completedNCT02788565What this trial is testingQuality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursWho this might be right forGastroenteropancreatic Neuroendocrine Tumours Ipsen 156
Testing effectiveness (Phase 2)UnknownNCT03457844What this trial is testingAnlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3Who this might be right forGastroenteropancreatic Neuroendocrine Tumor G3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Not applicableUnknownNCT05268952What this trial is testingEvaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)Who this might be right forNeuroendocrine Tumors University Hospital, Antwerp 100
Testing effectiveness (Phase 2)Looking for participantsNCT06840821What this trial is testingEvaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin ReceptorsWho this might be right forAdvanced Solid Tumors Mainline Biosciences (Shanghai) Co., Ltd 156
Testing effectiveness (Phase 2)UnknownNCT04427787What this trial is testingA Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETWho this might be right forMetastatic Well Differentiated Neuroendocrine NeoplasmNeuroendocrine Tumors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 69
Not applicableLooking for participantsNCT07635316What this trial is testingTreatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Novartis Pharmaceuticals 4,023
Early research (Phase 1)Study completedNCT05262556What this trial is testingNP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasWho this might be right forGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more Amr Mohamed MD 15
Large-scale testing (Phase 3)Looking for participantsNCT06937905What this trial is testingTarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)Who this might be right forNeuroendocrine Carcinoma Intergroupe Francophone de Cancerologie Thoracique 129
Testing effectiveness (Phase 2)Study completedNCT02611024What this trial is testingPharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsWho this might be right forAdvanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more PharmaMar 316
Testing effectiveness (Phase 2)Study completedNCT03591731What this trial is testingNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)Who this might be right forNeuroendocrine Carcinoma Intergroupe Francophone de Cancerologie Thoracique 185
Early research (Phase 1)Study completedNCT01263353What this trial is testingSafety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System Novartis Pharmaceuticals 36
Not applicableLooking for participantsNCT07302100What this trial is testingNutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University HospitalWho this might be right forGastroenteropancreatic Neuroendocrine Tumor University Hospital, Strasbourg, France 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706What this trial is testingIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersWho this might be right forPeritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more Hospices Civils de Lyon 27
Early research (Phase 1)Not Yet RecruitingNCT07661420What this trial is testing211At-MABG in Adults With Advanced Neuroendocrine CancersWho this might be right forPheochromocytomaParagangliomaNeuroendocrine Tumors+3 more University of Pennsylvania 16
Not applicableStudy completedNCT05255133What this trial is testingEvaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA TreatmentWho this might be right forNeuroendocrine Tumors Universiteit Antwerpen 22
Not applicableLooking for participantsNCT06256705What this trial is testingMulti-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National CohortWho this might be right forGastroenteropancreatic Neuroendocrine TumorRadiotherapy Assistance Publique - Hôpitaux de Paris 80
Testing effectiveness (Phase 2)Ended earlyNCT01994213What this trial is testingFamitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Jiangsu HengRui Medicine Co., Ltd. 53
Testing effectiveness (Phase 2)Study completedNCT03079440What this trial is testingTEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more Asan Medical Center 31
Testing effectiveness (Phase 2)Study completedNCT03095274What this trial is testingDurvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginWho this might be right forNeuroendocrine TumorsNeuroendocrine Neoplasm of Lung Grupo Espanol de Tumores Neuroendocrinos 126